

## Praxis Precision Medicines to Present at Upcoming Investor Conferences

March 3, 2023

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- <u>Praxis Precision Medicines</u>, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:

## • 43<sup>rd</sup> Annual TD Cowen Health Care Conference

o Orphan epilepsies panel on Monday, March 6, 2023 at 12:50 p.m. ET

## Needham Neuroscience Forum

o Fireside chat on Wednesday, March 15, 2023 at 2:00 p.m. ET

The events will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at <a href="https://www.praxismedicines.com">www.praxismedicines.com</a>. Replays of the webcasts will be available on Praxis' website for at least 30 days following the events.

## **About Praxis**

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit <a href="https://www.praxismedicines.com">www.praxismedicines.com</a> and follow us on <a href="https://www.praxismedicines.com">LinkedIn</a> and <a href="https://www.praxismedicines.com">Twitter</a>.

Investor Contact Alex Kane Praxis Precision Medicines investors@praxismedicines.com 617-300-8481 Media Contact Ian Stone Canale Communications Ian.stone@canalecomm.com 619-849-5388